-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Spyre Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2021 to Q2 2024.
- Spyre Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 45.3M shares, a 1085% increase year-over-year.
- Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6.9M shares, a 105% increase from 2022.
- Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 3.37M shares, a 28.2% increase from 2021.
- Spyre Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 2.63M shares, a 95.1% decline from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)